{
    "key_points": [
        "Pfizer, BioNTech, and Moderna poised to earn billions from COVID-19 booster shots, potentially echoing the $6 billion annual flu vaccine market.",
        "Governments in Chile, Germany, and Israel have started offering booster shots due to the Delta variant, despite debates on their necessity.",
        "Pfizer, BioNTech, and Moderna have secured over $60 billion in sales for 2021 and 2022, including initial vaccines and potential boosters.",
        "Revenue forecasts for Pfizer/BioNTech and Moderna in 2023 from boosters are over $6.6 billion and $7.6 billion, respectively.",
        "Evidence of waning antibody levels and breakthrough infections support the need for boosters, yet the extent of necessity remains debated.",
        "There's uncertainty on how many people will need boosters and how competition will affect the booster shot market.",
        "Pfizer expects a third dose necessity 6 to 8 months after full vaccination, with regular boosters afterward.",
        "COVID booster market could mimic the flu shot market, with developed country vaccination rates around 50%, and notable competition keeping prices in check.",
        "Pfizer and Moderna initially may have greater pricing power for their boosters until more competitors enter the market.",
        "U.S. government paying for the shots could prevent price increases, with efforts underway to test mix-and-match booster strategies."
    ],
    "spokespersons": [
        "Stephen Hoge (President, Moderna)",
        "Dave Ross (Executive, CSL's flu vaccine unit Seqirus)",
        "Steve Chesney (Analyst, Atlantic Equities)",
        "Damien Conover (Analyst, Morningstar)",
        "Vamil Divan (Analyst, Mizuho Securities)",
        "Bijan Salehizadeh (Managing Director, Navimed Capital)"
    ],
    "article_type": "general reporting",
    "dateline": "NEW YORK, Aug 13 (Reuters)",
    "audience": "general public",
    "stance": "neutral"
}